111 ROE 2018-2026 | YI
Current and historical return on equity (ROE) values for 111 (YI) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| 111 ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2026-03-31 | $-0.01B | $-0.10B | 12.75% |
| 2025-12-31 | $-0.01B | $-0.10B | 10.23% |
| 2025-09-30 | $-0.01B | $-0.10B | 10.58% |
| 2025-06-30 | $-0.01B | $-0.09B | 10.81% |
| 2025-03-31 | $-0.01B | $-0.09B | 10.00% |
| 2024-12-31 | $-0.01B | $-0.09B | 10.29% |
| 2024-09-30 | $-0.04B | $-0.09B | 41.86% |
| 2024-06-30 | $-0.05B | $-0.08B | 58.02% |
| 2024-03-31 | $-0.05B | $-0.08B | 70.90% |
| 2023-12-31 | $-0.06B | $-0.07B | 80.87% |
| 2023-09-30 | $-0.04B | $-0.06B | 65.08% |
| 2023-06-30 | $-0.04B | $-0.06B | 72.41% |
| 2023-03-31 | $-0.05B | $-0.05B | 88.89% |
| 2022-12-31 | $-0.06B | $-0.05B | 124.35% |
| 2022-09-30 | $-0.06B | $-0.04B | 162.03% |
| 2022-06-30 | $-0.09B | $-0.03B | 306.90% |
| 2022-03-31 | $-0.10B | $-0.01B | 869.57% |
| 2021-12-31 | $-0.11B | $0.01B | -1135.14% |
| 2021-09-30 | $-0.11B | $0.03B | -354.47% |
| 2021-06-30 | $-0.09B | $0.05B | -170.30% |
| 2021-03-31 | $-0.07B | $0.07B | -113.41% |
| 2020-12-31 | $-0.07B | $0.08B | -90.03% |
| 2020-09-30 | $-0.07B | $0.09B | -76.67% |
| 2020-06-30 | $-0.07B | $0.11B | -66.35% |
| 2020-03-31 | $-0.07B | $0.12B | -58.90% |
| 2019-12-31 | $-0.07B | $0.14B | -51.71% |
| 2019-09-30 | $-0.07B | $0.16B | -42.50% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.057B | $1.795B |
| 111, Inc. operates as a digital and mobile healthcare platform. The Company offers pharmacy distribution, medical consultancy, e-prescription and other services. 111, Inc. is headquartered in Shanghai, China. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $24.733B | 27.19 |
| Tempus AI (TEM) | United States | $7.677B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $4.429B | 38.86 |
| Doximity (DOCS) | United States | $3.888B | 16.84 |
| IRhythm Holdings (IRTC) | United States | $3.724B | 0.00 |
| 10x Genomics (TXG) | United States | $2.973B | 0.00 |
| Privia Health (PRVA) | United States | $2.810B | 131.59 |
| Hinge Health (HNGE) | United States | $2.789B | 0.00 |
| Heartflow (HTFL) | United States | $2.311B | 0.00 |
| Omnicell (OMCL) | United States | $1.564B | 43.00 |
| Inspire Medical Systems (INSP) | United States | $1.555B | 20.94 |
| Enovis (ENOV) | United States | $1.405B | 7.40 |
| Butterfly Network (BFLY) | United States | $1.047B | 0.00 |
| Azenta (AZTA) | United States | $1.023B | 41.13 |
| Clover Health Investments (CLOV) | United States | $1.013B | 0.00 |
| Talkspace (TALK) | United States | $0.864B | 103.40 |
| Schrodinger (SDGR) | United States | $0.839B | 0.00 |
| Phreesia (PHR) | United States | $0.490B | 50.38 |
| Fulgent Genetics (FLGT) | United States | $0.429B | 0.00 |
| Standard BioTools (LAB) | United States | $0.345B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.322B | 0.00 |
| CapsoVision (CV) | United States | $0.311B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.279B | 0.00 |
| Claritev (CTEV) | United States | $0.269B | 0.00 |
| TruBridge (TBRG) | United States | $0.268B | 8.60 |
| Evolent Health (EVH) | United States | $0.260B | 0.00 |
| Carlsmed (CARL) | United States | $0.239B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.196B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.189B | 0.00 |
| CareCloud (CCLD) | United States | $0.115B | 8.18 |
| Nyxoah SA (NYXH) | Belgium | $0.111B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.102B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.101B | 0.00 |
| American Well (AMWL) | United States | $0.086B | 0.00 |
| Outset Medical (OM) | United States | $0.077B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.073B | 0.00 |
| Pulmonx (LUNG) | United States | $0.058B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.052B | 0.00 |
| Precipio (PRPO) | United States | $0.049B | 0.00 |
| HeartBeam (BEAT) | United States | $0.047B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.034B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.018B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.009B | 0.00 |
| Zhongchao (ZCMD) | China | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.002B | 0.00 |
| PROFUSA (PFSA) | United States | $0.001B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |